AstraZeneca’s Chief Executive Officer, Pascal Soriot, will accompany U.K. Prime Minister Keir Starmer on his first state visit to China in eight years, joining a delegation of nearly 60 business and cultural organizations. The trip, scheduled for Thursday, includes meetings with President Xi Jinping and Premier Li Qiang to discuss expanded trade links, increased pharmaceutical supply agreements and co-investment in biotech research. Soriot’s participation underscores AstraZeneca’s strategic focus on strengthening its presence in one of its fastest-growing markets, where the company reported double-digit revenue growth in its China operations during the last fiscal year.

Analysts at Citigroup have designated AstraZeneca as their top pick among European pharmaceutical firms, upgrading the stock to a Buy rating. In their report, the team highlighted the company’s late-stage oncology pipeline—featuring three Phase III assets expected to reach regulatory decision points over the next 18 months—as a key driver of potential earnings acceleration. Citi’s research forecasts a compound annual growth rate of 8% in core earnings through 2028, reflecting anticipated margin expansion and milestone payments from recent licensing deals.

On the back of the positive broker commentary and news flow from the China trip, AstraZeneca shares outperformed the broader healthcare sector in the latest trading session, advancing by over one percent while the sector average rose by less than half a percent. Trading volumes surged to nearly twice the ten-day average, indicating elevated investor interest ahead of the company’s upcoming full-year results, scheduled for release next month. Market participants are watching closely for updated guidance on capital allocation and R&D spend targets.